5 result(s) for 'CD68'
1 - 5 of 5 results for 'CD68'
Sort by
Show
Antigen Background
The CD68 molecule is a 110 kD intracellular glycoprotein primarily reported to be associated with cytoplasmic granules and to a lesser extent the membranes of macrophages. Markers to CD68 antigen are the most frequently used for the identification of macrophages in immunohistochemistry; however, CD68 is also found in monocytes, neutrophils, basophils and large lymphocytes. The function of the CD68 molecule is not certain but th...
Phenotyping Tumor Microenvironment Using DNA Barcoded Multiplex Technology Chifei Sun GSK IVIVTBIBCellular Biomarkers Collegeville, PA
I have no conflict of interests with Leica Biosystems, Ultivue and Indica Labs. – All the materials used in this presentation are for educational purpose only. – The human biological samples were sourced ethically, and their research use was in accord with the terms of the informed consents under an IRB/EC approved protocol. Statement 9/25/2020 2
Understand the complexity of tumor microenvironment and its importance in drug development – Introduce the Ultivue DNA barcoding and exchange technology for multiplex immunofluorescence – Highlight the processes of image fusion, spatial analysis and colocalization of markers on individual cells Learning...
Slide 1
Hello, hello; thank you so much for that introduction. Let's get started. Oh, I'm sorry, I just need to hit this next button here. So my name is Mark Lawson.
Thank you for joining us in this webinar. I'm here to present BOND RX tips, tricks, and optimization. It's going to be a user guide from the BOND RX and chromogenic multiplexing in the research application.
Slide 2
So, my name is Mark Lawson. I'm an application specialist on the Life Sciences team at Leica Biosystems I provide technical support for the Life Sciences portfolio, including but not limited to the BOND RX, the BOND RXm, and a wide array of reagents. So I've worked in the histology field for about 15 years and in both clinical and research spaces. I started off as a histotechnologist and worked my way up...
It’s Time for TIME Alexander “Sandy” Borowsky Professor of Pathology and Laboratory Medicine Center for Immunology and Infectious Diseases
Disclosures Bristol-Meyers Squibb/Celgene: Funded through Investigator Sponsored Research (ISR) program. Discovery proposal. Leica/Aperio: Funded to run the “Genesis” study for primary diagnosis from whole slide images. Honorarium for this presentation. Histolix: Slide-free histology (Levenson and Fereidouni). Pfizer: Pfizer Protocol A9001502, Treatment Resistance Following Therapies (TRANSLATE) site PI. Agenda: In contracting to join the “FLEX” registry. None of these has actually paid me, only funding for the research projects.
Objectives • Introduction into the complexity of the TIME and the development of new cancer treatments though di...
Biomarkers
AE1/AE3 (1)
AMACR (2)
BCL6 (1)
CD163 (2)
CD20 (2)
CD3 (9)
CD4 (5)
CD68 (5)
CD8 (10)
CDX2 (2)
CK20 (5)
Ck5 (4)
...